The case for low-level BACE1 inhibition for the prevention of Alzheimer disease

Nature Reviews Neurology, Published online: 21 September 2021; doi:10.1038/s41582-021-00545-1To date, all phase III trials of β-site amyloid precursor protein (APP)-cleaving enzyme (BACE) inhibitors for Alzheimer disease were either discontinued or produced negative results. Here the authors present their opinion that BACE inhibitors still hold promise as a preventative therapy for Alzheimer disease and outline a series of experiments to inform future trials.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research

Related Links:

This study, still the only one of its kind, would evolve into her life ’s work, which focused on the mental changes that occur in both healthy and physically impaired people as they age, eventually helping guide the field of Alzheimer research.  “What Lissy Jarvik accomplished in her lifetime is truly remarkable,” said Dr. Alex Young, interim chair of the department of psychiatry and biobehavioral sciences and interim director of the Semel Institute for Neuroscience&Human Behavior at the medical school. “Her seminal contributions to the field of psychogeriatrics and Alzheimer’s resear...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Neurology, Psychiatry, Geriatrics, News, Source Type: news
Unfortunately, when faced with a serious health issue, even the most rational person can be led to believe implausible Alzheimer cure claims.
Source: FDA Consumer Health Information Updates - Category: Consumer Health News Authors: Source Type: news
In conclusion, we found copper inhibited pCREB/BDNF signaling pathway by prevent CREB from phosphorylation, further found that oxidative damage not only inhibited neuroprotective signaling pathways and induced apoptosis, but activated antioxidant protection signals Nrf2/HO-1/NQO1 signaling pathway.
Source: Journal of Applied Toxicology - Category: Toxicology Authors: Tags: RESEARCH ARTICLE Source Type: research
Yaniv Heled (Georgia State University), Ana Santos Rutschman (Saint Louis University), Liza Vertinsky (Emory University), Regulatory Reactivity in FDA's Approval of the Alzheimer's Disease Drug Aducanumab (Aduhelm), Regul. Rev. (2021): On June 7, 2021, the U.S. Food and Drug Administration...
Source: HealthLawProf Blog - Category: Medical Law Authors: Source Type: blogs
Sponsored The ADvance II Study sponsored by Functional Neuromodulation is currently seeking volunteers to participate in a clinical trial for mild Alzheimer’s disease. With a lack of effective long-term treatments, researchers are working hard to find new and better future treatments for patients with Alzheimer’s. Advances in treatment are possible through volunteers participating in clinical research studies like ADvance II. The ADvance II Study is researching the use of a surgically implanted device that delivers mild electrical pulses to specific areas of the brain in people with Alzheimer’s. This deep...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
Source: Neurological Sciences - Category: Neurology Source Type: research
Before the advent of the first senolytic drugs capable of selectively destroying senescent cells, it was thought by many that progress towards producing rejuvenation in the old via the safe elimination of senescent cells from the body would require the identification of surface markers that are distinctive to the state of senescence. Given a surface marker that clearly and distinctively identifies a cell population, a broad range of strategies become available for the development of targeted therapies. As it turned out,, however, the first senolytics took advantage of the peculiarities of the internal state of senescent ce...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Study tests if western diet contributes to the risk of developing Alzheimer's disease.
Source: PsyBlog | Psychology Blog - Category: Psychiatry & Psychology Authors: Tags: Dementia subscribers-only Source Type: blogs
Patients with chronic neuropathic pain (NP) have a significantly increased risk of central nervous degeneration. Trigeminal neuralgia (TN) is a typical NP, and this manifestation is more obvious. In addition to severe pain, patients with TN are often accompanied by cognitive dysfunction and have a higher risk of central nervous system degeneration, but the mechanism is not clear. The NOD-like receptor 3 (NLRP3) inflammasome assembles inside of microglia on activation, which plays an important role in neurodegeneration such as Alzheimer disease. MCC950 is a specific blocker of NLRP3 inflammasome, which can improve the perfo...
Source: Shock - Category: Emergency Medicine Tags: Basic Science Aspects Source Type: research
More News: Alzheimer's | Brain | Neurology